{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:54:50Z","timestamp":1777679690184,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,10]]},"DOI":"10.7759\/cureus.104971","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T09:01:37Z","timestamp":1773133297000},"source":"Crossref","is-referenced-by-count":1,"title":["Fatal Interstitial Pneumonitis During Combined Degarelix, Darolutamide, and Docetaxel Therapy for Metastatic Prostate Cancer"],"prefix":"10.7759","author":[{"given":"Fumihiro","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaku","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Kamijo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE- 1): a multicentre, open-label, randomised, phase 3 study","volume":"399","author":"Fizazi K","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, et al.. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE- 1): a multicentre, open-label, randomised, phase 3 study. Lancet. 2022, 399:1695-707. 10.1016\/S0140-6736(22)00367-1","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith MR","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, et al.. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022, 386:1132-42. 10.1056\/NEJMoa2119115","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James ND","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, et al.. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017, 377:338-51. 10.1056\/NEJMoa1702900","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney CJ","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, et al.. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015, 373:737-46. 10.1056\/NEJMoa1503747","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James ND","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, et al.. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016, 387:1163-77. 10.1016\/S0140-6736(15)01037-5","journal-title":"Lancet"},{"key":"ref6","article-title":"Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer","volume":"32","author":"Tamiya A","year":"2012","unstructured":"Tamiya A, Naito T, Miura S, et al.. Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer. Anticancer Res. 2012, 32:1103-6.","journal-title":"Anticancer Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore ND","year":"2020","unstructured":"Shore ND, Saad F, Cookson MS, et al.. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020, 382:2187-96. 10.1056\/NEJMoa2004325","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001342","article-title":"Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide","volume":"383","author":"Fizazi K","year":"2020","unstructured":"Fizazi K, Shore N, Tammela TL, et al.. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med. 2020, 383:1040-9. 10.1056\/NEJMoa2001342","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5942-4","article-title":"Interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy: a case report","volume":"19","author":"Yanai Y","year":"2019","unstructured":"Yanai Y, Kosaka T, Hongo H, Oya M. Interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy: a case report. BMC Cancer. 2019, 19:720. 10.1186\/s12885-019-5942-4","journal-title":"BMC Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/iju5.12420","article-title":"Interstitial lung disease induced by apalutamide therapy for castration-resistant prostate cancer: a report of a rare case","volume":"5","author":"Kirishima F","year":"2022","unstructured":"Kirishima F, Shigematsu Y, Kobayashi K. Interstitial lung disease induced by apalutamide therapy for castration-resistant prostate cancer: a report of a rare case. IJU Case Rep. 2022, 5:153-5. 10.1002\/iju5.12420","journal-title":"IJU Case Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-022-00592-5","article-title":"Interstitial pneumonia after regression by olaparib for neuroendocrine prostate cancer with BRCA1 mutation: a case report","volume":"12","author":"Kaitsumaru M","year":"2023","unstructured":"Kaitsumaru M, Shiota M, Takamatsu D, et al.. Interstitial pneumonia after regression by olaparib for neuroendocrine prostate cancer with BRCA1 mutation: a case report. Int Cancer Conf J. 2023, 12:131-6. 10.1007\/s13691-022-00592-5","journal-title":"Int Cancer Conf J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.802","article-title":"Docetaxel-induced interstitial lung disease among patients with breast cancer: a case series and review of literature","volume":"9","author":"Hettiarachchi SM","year":"2021","unstructured":"Hettiarachchi SM, Thilakaratne D, Dharmasena D, Rathnapala A, Abeysinghe P, Perera E. Docetaxel-induced interstitial lung disease among patients with breast cancer: a case series and review of literature. Respirol Case Rep. 2021, 9:00802. 10.1002\/rcr2.802","journal-title":"Respirol Case Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100404","article-title":"Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment","volume":"7","author":"Conte P","year":"2022","unstructured":"Conte P, Ascierto PA, Patelli G, et al.. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open. 2022, 7:100404. 10.1016\/j.esmoop.2022.100404","journal-title":"ESMO Open"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7100356","article-title":"Drug-induced interstitial lung disease: a systematic review","volume":"7","author":"Skeoch S","year":"2018","unstructured":"Skeoch S, Weatherley N, Swift AJ, et al.. Drug-induced interstitial lung disease: a systematic review. J Clin Med. 2018, 7:356. 10.3390\/jcm7100356","journal-title":"J Clin Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-13-39","article-title":"Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches","volume":"13","author":"Matsuno O","year":"2012","unstructured":"Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res. 2012, 13:39. 10.1186\/1465-9921-13-39","journal-title":"Respir Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000079633","article-title":"Interstitial lung disease induced by drugs and radiation","volume":"71","author":"Camus P","year":"2004","unstructured":"Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration. 2004, 71:301-26. 10.1159\/000079633","journal-title":"Respiration"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/469853-fatal-interstitial-pneumonitis-during-combined-degarelix-darolutamide-and-docetaxel-therapy-for-metastatic-prostate-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T09:01:37Z","timestamp":1773133297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/469853-fatal-interstitial-pneumonitis-during-combined-degarelix-darolutamide-and-docetaxel-therapy-for-metastatic-prostate-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.104971","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,10]]}}}